Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C] ABBV-932 in Healthy Male Volunteers
NCT06953934Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABBV-932, sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration at 86 days, Time to Cmax at 86 days and 5 more. Started May 2026; status: completed.
02
Drugs
ABBV-932
Beyond the preview
Go deeper on NCT06953934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953934.